Information Provided By: 
Fly News Breaks for November 7, 2019
RARX
Nov 7, 2019 | 18:40 EDT
Stifel analyst Stephen Willey downgraded RA Pharmaceuticals to Hold from Buy with a price target of $48, down from $50. The downgrade follows last weeks announcement that UCB and Ra Pharmaceuticals have entered into a merger agreement, and the analyst still expects the transaction to close in Q1 of next year. Willey adds the new price target reflects the proposed acquisition price on a fully-diluted basis.
News For RARX From the Last 2 Days
There are no results for your query RARX
